Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib combined with donor lymphocyte infusion for relapsed multiple myeloma after allogeneic stem cell transplantation
NL-OMON25090Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University Medical Center Utrecht. Primary endpoint: Response rate. Planned start May 2007; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON25090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25090.